Unknown

Dataset Information

Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide.


ABSTRACT:

Background & aims

Bulevirtide is a first-in-class entry inhibitor antiviral treatment for chronic hepatitis D. The viral kinetics during bulevirtide therapy and the effect of combining bulevirtide with pegylated-interferon (Peg-IFN) are unknown.

Methods

We used mathematical modelling to analyze the viral kinetics in two French observational cohorts of 183 patients receiving bulevirtide with or without Peg-IFN for 48 weeks.

Results

The efficacy of bulevirtide in blocking cell infection was estimated to 90.3%, whereas Peg-IFN blocked viral production with an efficacy of 92.4%, albeit with large inter-individual variabilities. The addition of Peg-IFN to bulevirtide was associated with a more rapid virological decline, with a rate of virological response (>2 log of declin

SUBMITTER: El Messaoudi S 

PROVIDER: S-EPMC11295569 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature